Federal advisory sits at the center of this dementia and brain health question.

In January 2026, the Federal Advisory Council on Alzheimer’s Research, Care, and Services received significant new leadership and membership appointments aimed at strengthening the national response to dementia. HHS Secretary Robert F. Kennedy Jr.

announced the appointment of Michelle Branham, Secretary of Florida’s Department of Elder Affairs, as the new chair, along with Katheryn Newkirk as vice-chair, plus ten additional public members bringing diverse expertise in aging services, public health, and dementia advocacy. This restructured council represents a strategic shift in how the federal government approaches Alzheimer’s disease policy, research coordination, and the practical support systems that patients and families depend on. The new members were formally sworn in at the council’s first meeting on February 9, 2026, marking the beginning of what many experts view as a critical period for advancing both basic research and real-world care solutions.

Who Are the New Leaders Steering the Alzheimer’s Advisory Council?
What Expertise Do the Ten New Council Members Bring?
What Role Does This Council Actually Play in Addressing Alzheimer’s Disease?
How Will This Leadership Change Affect Alzheimer’s Research and Care Priorities?
What Are the Key Challenges This Council Will Face?
Why Does Including a Patient Advocate on the Council Matter?
What Can We Expect From This Council in the Coming Years?
Conclusion

Who Are the New Leaders Steering the Alzheimer’s Advisory Council?

Michelle Branham’s appointment as chair brings more than 25 years of experience in Alzheimer’s disease public policy and public health, credentials developed through her work as Florida’s Secretary of Elder Affairs. Florida, with one of the nation’s oldest populations, has positioned Branham as someone deeply familiar with both the administrative challenges of serving aging populations and the specific burden that dementia places on state health systems and families.

Her background suggests the council will likely emphasize the connection between research findings and their implementation in real-world healthcare and social service systems—a gap that has historically frustrated both researchers and family caregivers. Katheryn Newkirk’s role as vice-chair adds another layer of institutional knowledge, though details about her specific background have been less extensively covered in public announcements. The pairing of chairs typically reflects an intentional balance; in this case, strong state-level administrative experience combined with what federal announcements suggest is complementary expertise in another critical area of the Alzheimer’s ecosystem.

Who Are the New Leaders Steering the Alzheimer's Advisory Council?

What Expertise Do the Ten New Council Members Bring?

The ten newly appointed public members represent a deliberate effort to diversify the council’s perspective beyond traditional academic research circles. The appointees include senior leadership in aging services, practitioners with deep dementia advocacy experience, public health specialists, and significantly, a patient advocate living with dementia. This last appointment is noteworthy—including someone actively experiencing the disease themselves ensures that abstract policy discussions remain grounded in the lived reality of diagnosis, treatment decisions, cognitive decline, and the impact on family members. One of the identified new members is Dr.

Randall Bateman, Director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis. Bateman was elected to the National Academy of Medicine in 2020, in part for pioneering work in developing blood-based biomarkers that can detect Alzheimer’s changes years before symptoms emerge. His presence on the council signals that the federal advisory body will likely prioritize biomarker research and early detection—areas that could eventually transform how the disease is diagnosed and managed.

What Role Does This Council Actually Play in Addressing Alzheimer’s Disease?

The Advisory Council on Alzheimer’s Research, Care, and Services was established in 2011 under the National Alzheimer’s Project Act (NAPA), which created a framework for coordinating federal efforts across multiple agencies to combat the disease. The council meets quarterly to provide advice to the HHS Secretary on strategies for reducing the burden of Alzheimer’s disease and related dementias across research, clinical care, patient support, and public health initiatives. This structure means the council influences—though does not directly control—how federal resources flow toward research funding, how guidelines are developed, and how different government agencies coordinate their Alzheimer’s initiatives.

The council’s recommendations have historically shaped priorities for the National Institute on Aging, funding mechanisms through the National Institutes of Health, and policy directions for the Centers for Medicare and Medicaid Services. However, there is often a gap between what the council recommends and what actually reaches families and patients through the healthcare system, especially outside major academic medical centers. This new leadership team will need to address that translation problem if their work is to have meaningful real-world impact.

What Role Does This Council Actually Play in Addressing Alzheimer's Disease?

How Will This Leadership Change Affect Alzheimer’s Research and Care Priorities?

The composition of the new council suggests several likely shifts in federal priorities. Branham’s state-level experience indicates potential movement toward better integration of research into state aging networks and long-term care systems—areas that have historically received less federal attention than basic laboratory science. Similarly, the inclusion of a patient advocate on the council may elevate questions about quality of life, behavioral symptom management, and caregiver support, not just biomedical research endpoints.

Dr. Bateman’s appointment specifically signals that blood-based biomarker research will likely receive continued emphasis, potentially accelerating the timeline for translating these tests from research settings into routine clinical practice. This matters because blood biomarkers offer a simpler, less invasive alternative to current diagnostic methods (PET scans and spinal fluid testing) and could enable earlier diagnosis in community settings. However, the challenge remains ensuring that early diagnosis translates to effective early interventions—a problem the field has grappled with for years.

What Are the Key Challenges This Council Will Face?

The Alzheimer’s research and care landscape remains fragmented across federal agencies, academic institutions, pharmaceutical companies, and state healthcare systems, with insufficient coordination between these silos. The new council will need to navigate complex political dynamics around research funding priorities, especially given competing demands for federal health dollars and evolving priorities within the Trump administration (given the January 2026 appointment timeframe).

One significant challenge is the “research-to-practice gap”—findings from clinical trials and laboratory research often take years or decades to reach patients in real-world settings. Branham’s state-level background suggests an awareness of this problem, but solving it requires sustained coordination across entities that don’t always have aligned incentives. Additionally, the council must address the crisis of caregiver burnout and family financial strain related to dementia care, issues that fall somewhat outside traditional research councils’ scope but that are central to the actual lived experience of dementia.

What Are the Key Challenges This Council Will Face?

Why Does Including a Patient Advocate on the Council Matter?

Most federal advisory councils lean heavily toward academic researchers, clinicians, and industry representatives. The deliberate appointment of someone living with dementia to this council acknowledges a reality that patient advocacy groups have long emphasized: people with the disease and their families have crucial insights about what treatments are actually worth pursuing, what gaps in care are most damaging, and what support systems would make the greatest difference in daily life.

This person’s voice can help prevent the council from prioritizing research endpoints that look good in clinical papers but don’t meaningfully improve patients’ lives. However, there is a limitation to this representation: one patient advocate, while valuable, cannot fully capture the diversity of dementia experiences or represent all family perspectives. The council will need to ensure it remains connected to broader patient advocacy communities and hears from diverse populations, not just those with access to major medical centers or research trials.

What Can We Expect From This Council in the Coming Years?

With new leadership in place as of February 2026 and quarterly meetings scheduled, the council will likely begin shaping recommendations that influence federal funding decisions, research priorities, and care coordination initiatives across fiscal years 2027 and beyond. The presence of both research leaders like Bateman and administrative experts like Branham suggests the council is positioning itself to bridge the gap between discovery and implementation—a transition the field critically needs.

The broader federal context matters here: how much resources Congress allocates to Alzheimer’s research, whether the administration prioritizes long-term care reform, and how private sector partners engage with federal guidance will all shape what this council can accomplish. What seems clear is that the new members bring a more diverse perspective on what “addressing Alzheimer’s disease” means—not just funding more research, but improving how care is delivered, supporting families who carry the burden of caregiving, and ensuring that new discoveries actually reach patients who need them.

Conclusion

The appointment of Michelle Branham, Katheryn Newkirk, and ten additional council members in early 2026 represents a meaningful restructuring of how the federal government coordinates its approach to Alzheimer’s disease. Bringing state-level administrative expertise, research leadership in blood biomarkers, dementia advocacy perspectives, and a patient voice to the table creates potential for more comprehensive and practical guidance on addressing this disease across the research-care spectrum. The council’s quarterly meetings and recommendations will influence federal research funding, clinical practice guidelines, and how different agencies coordinate their Alzheimer’s initiatives.

For patients and families, the most important indicator of success will be whether this reconstituted council actually accelerates the translation of research into treatments and services that reach beyond major academic centers. That requires sustained attention to both cutting-edge science and the messy realities of how healthcare and support systems actually work at the state and local level. The coming quarterly meetings and subsequent recommendations will offer the first clear signal of whether this new leadership can bridge that gap.